Neglected Tropical Disease Treatment Market
Report ID: SQMIG35I2814
Report ID: SQMIG35I2814
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2814 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
156
|Figures:
78
Global Neglected Tropical Disease Treatment Market size was valued at USD 3.3 Billion in 2024 and is poised to grow from USD 3.6 Billion in 2025 to USD 7.17 Billion by 2033, growing at a CAGR of 9.0% during the forecast period (2026-2033).
The primary driver of the neglected tropical disease treatment industry is the large persistent public health burden in low income settings that sustains demand for scalable interventions. This market includes pharmaceuticals, diagnostics, delivery platforms and services for schistosomiasis, lymphatic filariasis and trachoma, and it matters because these conditions erode productivity, child development and health system resilience. In recent decades coordinated efforts such as mass drug administration, product development partnerships and WHO elimination roadmaps shifted activity from ad hoc charity toward structured procurement and supply chains, illustrated by donation programs from manufacturers and expanded disease mapping to optimize resource allocation globally.
One major reason behind increasing development of the overall global neglected tropical disease treatment market is an increased financing presence in terms of both public and private entities' partnerships that enable scalability and reduce the barriers of entry to the overall market. When manufacturers donate their drugs or support the distribution of their products through programs such as Merck's Mectizan Program and the International Trachoma Initiative, national programs are able to conduct mass drug administration (MDA) at a large scale which produces demonstrable declines in disease prevalence and creates sustainable cycles of procurement, making the marketplace a more attractive place for suppliers. In addition, improved diagnostics and geospatial mapping have maximized the efficiency of treatment funds by directing treatments to the areas of greatest need; whereas, local production incentives along with modernized regulatory processes have created the type of commercial viability necessary to attract investment in product formulations.
How is AI improving market access for neglected tropical disease treatments?
AI is improving market access for neglected tropical disease treatments by accelerating discovery, improving diagnostics, optimizing supply chains and informing program decisions. Key aspects include machine learning for target identification and clinical trial design, AI driven image and symptom recognition for point of care diagnosis, and geospatial models that guide distribution to hard to reach communities. The current market is still under resourced and fragmented, yet growing collaboration between research groups, non profit developers and health programmes is turning pilots into more predictable pipelines and leaner delivery systems. Examples include DNDi using AI tools, WHO linked AI training for programme staff, and strengthened academic partnerships focused on digital solutions.
Sanofi in February 2026, reported a regulatory milestone for acoziborole that creates a treatment ready for wider use. Coupled with AI enabled surveillance and logistics platforms this development can speed distribution to remote patients, reduce stockouts and support targeted rollout strategies that improve market uptake and operational efficiency.
Market snapshot - (2026-2033)
Global Market Size
USD 3.3 Billion
Largest Segment
Soil-Transmitted Helminthiasis
Fastest Growth
Dengue
Growth Rate
9.0% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global neglected tropical disease treatment market is segmented by disease type, treatment type, drug class, distribution channel, end user and region. Based on disease type, the market is segmented into Dengue, Chagas Disease, Leishmaniasis, Lymphatic Filariasis, Schistosomiasis, Onchocerciasis, Trachoma, Soil-Transmitted Helminthiasis, Human African Trypanosomiasis and Others. Based on treatment type, the market is segmented into Drug Therapy, Vaccines and Supportive Therapy. Based on drug class, the market is segmented into Antiparasitic Drugs, Antibacterial Drugs, Antiviral Drugs and Antifungal Drugs. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Government & NGO Supply Programs. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Community Healthcare Centers, Research Institutes, Public Health Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Government & NGO supply programs segment dominates with neglected tropical disease treatment market share because these coordinated channels centralize procurement, financing, and logistics to ensure consistent availability of medicines and preventive products for vulnerable populations. Their alignment with donor priorities and established supply chains reduces access barriers and incentivizes manufacturers to tailor products for programmatic needs, which in turn strengthens routine distribution, mass treatment campaigns, and sustained market demand for NTD therapeutics.
As per neglected tropical disease treatment market outlook, hospital pharmacies are emerging as the most rapidly expanding distribution channel due to closer integration with clinical care, improved inventory systems, and growing pharmacy-led counseling that supports treatment adherence. Their direct link to treating clinicians accelerates uptake of new therapies and outpatient regimens, creating commercial opportunities and partnership models that expand treatment access and bolster post marketing monitoring.
As per neglected tropical disease treatment market regional forecast, vaccines segment leads because preventive immunization shifts market focus toward durable population-level control, attracting sustained funding and public health prioritization that support long development and deployment timelines. Developers pursuing preventive solutions to treatment burden and recurring case management have been encouraged to procure anticipated procurement and collaborate in ways that shift their investment in the market from repeated therapy cycles to upstream prevention through new development and regulatory pathways.
As per neglected tropical disease treatment industry analysis, drug therapy is emerging as the most rapidly expanding treatment approach driven by innovation in antiparasitic chemistries, repurposed molecules, and combination regimens addressing resistance. Advance diagnostics and updated treatment guidelines are increasing the clinical usage of these types of drugs and also encouraging manufacturers to pursue new formulations of these drugs and outpatient treatment options, thus creating additional opportunities for manufacturers to grow their investment in these therapeutic areas.
To get detailed segments analysis, Request a Free Sample Report
The Asia Pacific region is in the forefront because to a combination of robust pharmaceutical manufacturing infrastructure, specialized research and development capabilities, and coordinated public health measures in important markets like Japan and South Korea. Regional integration of supply chains and export-oriented production hubs allow for effective scaling of medicines and diagnostics. Governments drive innovation via regulatory channels and financing incentives, while academia and private sector partnership speeds up product development and clinical translation. Collaborations with global health agencies and focused funding in diagnostic infrastructure boost market preparedness. Well-developed healthcare infrastructure encourages rapid uptake of innovative medicines and attractive trade networks enable delivery to neighbouring endemic markets. Taken together these characteristics generate a competitive climate that puts Asia Pacific at the forefront of treatment development and supply for neglected tropical illnesses.
Japan neglected tropical disease treatment market is supported by a developed biotech ecosystem, strong regulatory agencies and large-scale pharmaceutical manufacturing capabilities. Close collaboration between universities, research institutes and industry drives translational research and clinical development. Domestic production is backed by established quality control standards and competent contract manufacturing groups. Strategic public health programs and interaction with global health partners allow technology transfer and RD projects further enhancing treatment innovation and readiness.
As per neglected tropical disease treatment market regional outlook, South Korea is supported by a biotech sector, agile regulatory frameworks, and advanced manufacturing capacity. Collaboration among industry, hospitals, and research institutes accelerates clinical development and commercialization. Digital health integration and precise diagnostics enable efficient patient management. Government support and public private partnerships foster innovation, while robust logistics and trade links promote distribution and collaboration with international health partners to improve treatment availability.
As per neglected tropical disease treatment market regional forecast, North America is growing rapidly driven by scientific innovation, attractive commercial incentives and an integrated healthcare ecosystem. Deep clinical trial expertise, experienced contract research and manufacturing businesses and proactive regulatory engagement accelerate development routes for innovative treatments in the region. Strong private investment and strategic partnerships between biotech companies, academic institutions and philanthropic groups speed up bench to bedside translation. Patient advocacy and payer engagement promote access strategies while modern diagnostic platforms and digital health tools offer efficient illness management and post market surveillance. Cross-border cooperation and procurement capabilities help further position the region to support global treatment supply chains and shape standards of care for neglected tropical diseases.
As per neglected tropical disease treatment industry analysis, United States market is driven by its biotech sector, private investment, and clinical research base. Academic medical centers and specialized research networks allow efficient clinical evaluation and translational work. Patient advocacy and philanthropy funders’ engagement influences development priorities and access approaches. Commercialization and partnering capabilities supported by strong regulatory and manufacturing skills and experienced payer landscape extend treatment reach in endemic environments.
Canada is supported by a public healthcare system, strong academic research, and industry partnerships. Federal provincial coordination enhances research translation and clinical capacity. Public funding and philanthropy advance diagnostics and therapeutics. Emphasis on health equity and global engagement drives programs that improve access for underserved populations. Regulatory collaboration with international authorities and a manufacturing base enable Canada to participate in cross border supply initiatives.
Europe is also consolidating its position in the neglected tropical disease therapy sector by promoting cooperation between national research institutes, establishing harmonized regulatory frameworks and building strategic industry alliances. Investments in translational research and improved diagnostics provide capacity for targeted therapeutic development, along with strong manufacturing knowledge in key markets for reliable supply. Cross border clinical networks and public private collaborations that speed trial execution and innovation adoption. Together with manufacturers, policymakers and philanthropies build procurement and distribution strategies that prioritize access, strengthening global health pledges. Participation in international research consortia and technology transfer programs is active, leading to an impact beyond the limits of the region, therefore establishing Europe as a major contributor to the discovery, validation and delivery of treatments for neglected tropical illnesses. More interaction with patient advocates leads to uptake and equitable distribution across varied contexts.
Germany benefits from a strong pharmaceutical and biotech sector, high quality manufacturing, and established research centers. Collaboration between industry and universities accelerates translational science and clinical development. Regulatory expertise and strict quality standards support export confidence and international partnerships. Public private programs foster diagnostics and therapeutic innovation, while efficient logistics and experience in supply chains enable Germany to reliably contribute to global treatment distribution.
United Kingdom benefits from life sciences hubs, research hospitals, and translational focus. Integrated clinical trial networks and access to real world data through national health systems support efficient evaluation of new therapies. Collaboration among academic centers, industry, and philanthropic organizations accelerates innovation and access. Regulatory expertise and manufacturing capabilities enable the United Kingdom to engage in international partnerships and contribute globally to treatment programs.
France benefits from a strong research base, institutes, and biotech clusters. Collaboration between academic centers, research organizations, and industry advances translational research and therapeutic innovation. Expertise in vaccines, diagnostics, and manufacturing supports international partnerships. Public policy emphasis on global health and engagement in francophone endemic regions enables France to contribute to capacity building, clinical research, and distribution efforts that expand treatment access more broadly.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Expanded Public Health Initiatives
Increased Research And Development Collaboration
Limited Healthcare Infrastructure In Endemic Areas
Unpredictable Funding For Procurement
Request Free Customization of this report to help us to meet your business objectives.
Competitive dynamics in the global neglected tropical disease treatment industry are driven by university spinouts, specialized biotechs and non profit R&D partnerships deploying M&A, licensing and platform collaborations to bridge late stage development and access. Key market drivers tied to competition include AI enabled drug discovery and diagnostics partnerships such as DNDi with Atomwise and co development alliances like DNDi and AN2, plus recent acquisition activity that consolidates pipeline assets.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the neglected tropical disease treatment market growth is being driven primarily by the large persistent public health burden in low-income settings that sustains demand for scalable interventions, while limited healthcare infrastructure in many endemic areas remains a key restraint that complicates delivery and adherence. Asia Pacific currently dominates the market supported by strong manufacturing, R&D and coordinated public health programs, and government and NGO supply programs are the dominating distribution segment ensuring centralized procurement and mass treatment reach. A secondary driver is increased public and private financing and partnership models that de-risk supply, enable mass drug administration and attract investment into diagnostics and therapeutics. The neglected tropical disease treatment market trend due to increasing global health initiatives, rising government and non-profit funding, and growing awareness regarding infectious diseases affecting low-income populations.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 3.3 Billion |
| Market size value in 2033 | USD 7.17 Billion |
| Growth Rate | 9.0% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Neglected Tropical Disease Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Neglected Tropical Disease Treatment Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Neglected Tropical Disease Treatment Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Neglected Tropical Disease Treatment Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Neglected Tropical Disease Treatment Market size was valued at USD 3.3 Billion in 2024 and is poised to grow from USD 3.6 Billion in 2025 to USD 7.17 Billion by 2033, growing at a CAGR of 9.0% during the forecast period (2026-2033).
Competitive dynamics in the global neglected tropical disease treatment market are driven by university spinouts, specialized biotechs and non profit R&D partnerships deploying M&A, licensing and platform collaborations to bridge late stage development and access. Key market drivers tied to competition include AI enabled drug discovery and diagnostics partnerships such as DNDi with Atomwise and co development alliances like DNDi and AN2, plus recent acquisition activity that consolidates pipeline assets. 'GlaxoSmithKline plc', 'Pfizer Inc.', 'Merck & Co., Inc.', 'Johnson & Johnson', 'Sanofi S.A.', 'Novartis AG', 'Bayer AG', 'F. Hoffmann-La Roche Ltd.', 'AbbVie Inc.', 'AstraZeneca plc', 'Eisai Co., Ltd.', 'Takeda Pharmaceutical Company Limited', 'Bristol-Myers Squibb Company', 'Gilead Sciences, Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Cipla Limited', 'Sun Pharmaceutical Industries Limited', 'Lupin Limited', 'Aurobindo Pharma Limited', 'Dr. Reddy’s Laboratories Ltd.'
Expanded public health initiatives increase prioritization of neglected tropical disease programs by governments and health agencies, leading to strengthened supply chains, coordinated distribution, and broader outreach to affected communities. This encourages development and procurement of treatments, supports partnerships with manufacturers and non profit organizations, and reduces logistical barriers to reaching remote populations. Greater government commitment also fosters policy support and predictable funding streams that incentivize manufacturers to maintain and scale production capacity, thereby directly contributing to consistent market expansion and sustained access to therapies.
Public Private Innovation Collaborations: Strategic collaborations between industry, foundations, academic centers, and community organizations are accelerating development and delivery of treatments for neglected tropical diseases. These partnerships align commercial capabilities with public health priorities to share risks, enable technology transfer, and adapt supply chains to local contexts. Emphasis on capacity building, clinical research networks, and outcome based agreements fosters sustainable access and innovation tailored to endemic settings, improving adoption of new therapies while strengthening local systems and incentivizing investment in historically underserved disease areas.
Why does Asia Pacific Dominate the Global Neglected Tropical Disease Treatment Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
